Clinical trials: in Morocco
Bronchitis, Chronic, Bronchial Diseases
Greatest International Antiinfective Trial With Avelox
The observation period for each patient covered an initial treatment period with Avelox® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit…
- Trial name
- GIANT (NCT00932802)
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- 24 sites in Austria, Brazil and 22 more
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Iodine Deficiency
Study of the Effect of Iodized Oil Supplementation During Infancy
In iodine-deficient countries or regions that have inadequate iodized salt distribution, the World Health Organization (WHO) recommends choosing one of two methods to improve iodine intakes in breastfeeding infants: 1) iodine…
- Trial name
- INSIGHT (NCT01126125)
- Testing
- Iodized oil
- Where
- Morocco
- Volunteers
- 241 people
- Sponsor
- Swiss Federal Institute of Technology
Anemia
An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia
This multicenter, prospective, observational study will evaluate the quality of life and the factors that influence the quality of life of epoetin beta [Neorecormon] in patients with renal chronic anemia, who are on dialysis.
- Trial name
- NCT01105494
- Testing
- epoetin beta [NeoRecormon]
- Where
- Morocco
- Volunteers
- 6,000 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs
Primary Objective: To evaluate the efficacy of an intensive insulin regimen with insulin glargine and insulin glulisine in terms of change in Hemoglobin A1c (HbA1c) level from week 12 (visit 7) to week 24 (visit 10).
- Trial name
- CHANGING (NCT01203111)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE
- Where
- 10 sites in Algeria, Brazil and 8 more
- Volunteers
- 207 people
- Sponsor
- Sanofi
Hypertension
Treatment of Hypertension With Adalat® in Combination With Other Drugs
To investigate the therapeutic effectiveness of long acting nifedipine containing combination therapy in the treatment of hypertensive patients.
- Trial name
- NCT01118286
- Testing
- Nifedipine (Adalat, BAYA1040)
- Where
- 11 sites in Bahrain, Egypt and 9 more
- Volunteers
- 4,497 people
- Sponsor
- Bayer
Breast Cancer
Resource-sparing Post-mastectomy Radiotherapy in Breast Cancer
This study compares two different field set-ups in patients with breast cancer following a breast resection (mastectomy). These two set-ups are as follows: arm a - radiotherapy to the chest-wall only, and arm b - radiotherapy to…
- Trial name
- NCT01452672
- Testing
- Radiotherapy, Irradiation of the chest-wall and supraclavicular fossa
- Where
- 9 sites in Cuba, Egypt and 6 more
- Volunteers
- 600 people
- Sponsor
- International Atomic Energy Agency
Cervix Cancer
CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy
The purpose of this trial is to study clinical effects of two/four high dose rate (HDR) brachytherapy applications and teletherapy with or without weekly cisplatin in cervix cancer.
- Trial name
- NCT00122772
- Testing
- Radiotherapy, Radiotherapy/Cisplatin
- Where
- 11 sites in Austria, Brazil and 9 more
- Volunteers
- 601 people
- Sponsor
- International Atomic Energy Agency
Chronic Bronchitis
PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis
Primary Objective: The primary objective of the study is to demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in the reduction of Streptococcus pneumoniae (Sp) strains resistant to…
- Trial name
- NCT00132938
- Testing
- telithromycin
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 5,660 people
- Sponsor
- Sanofi
Dental Plaque
Chlorhexidine Mouthrinses and Plaque Control
The aim of the present study was to compare antiplaque effectiveness of two commercial mouthrinses: 0.12 % Chlorhexidine alcohol base (CLX-A) versus a diluted 0.1% Chlorhexidine non-alcohol base with 0.1% of Formaldehyde (CLX-F).
- Trial name
- NCT01138943
- Testing
- Synthodont, Soludent
- Where
- Morocco
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hôpital Militaire De Rabat
Acute Coronary Syndromes
LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes
Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes
- Trial name
- NCT00214630
- Testing
- rosuvastatin calcium, atorvastatin
- Where
- 56 sites in United States, Costa Rica and 3 more
- Volunteers
- 825 people
- Sponsor
- AstraZeneca
Hypertension
Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy
Primary Objective: To demonstrate that the antihypertensive efficacy of the fixed combination irbesartan/amlodipine 300/5 mg is superior to that of irbesartan 300 mg monotherapy in lowering systolic blood pressure (SBP) as…
- Trial name
- I-ADD (NCT00957554)
- Testing
- irbesartan/amlodipine, irbesartan
- Where
- 38 sites in Brazil, Colombia and 6 more
- Volunteers
- 435 people
- Sponsor
- Sanofi
Hypertension
Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy
Primary Objective: To demonstrate that the antihypertensive efficacy of the fixed combination irbesartan/amlodipine 150/5 mg is superior to that of amlodipine 5 mg monotherapy in lowering systolic blood pressure (SBP) as measured…
- Trial name
- I-COMBINE (NCT00956644)
- Testing
- irbesartan/amlodipine, amlodipine
- Where
- 40 sites in Brazil, Chile and 7 more
- Volunteers
- 406 people
- Sponsor
- Sanofi
Hypertension
Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension
The primary objective is to compare the efficacy of irbesartan/hydrochlorothiazide 300/25mg against valsartan/hydrochlorothiazide 160/25mg in reducing mean systolic blood pressure (SBP) as measured by home blood pressure…
- Trial name
- COSIMA2 (NCT00500604)
- Testing
- Irbesartan/hydrochlorothiazide, Valsartan/hydrochlorothiazide, Hydrochlorothiazide
- Where
- 14 sites in Egypt, Hong Kong and 12 more
- Volunteers
- 1,617 people
- Sponsor
- Sanofi
Hypertension
ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination
To compare the antihypertensive efficacy of the combination irbesartan/hydrochlorothiazide (HCTZ) using either a usual or an active elective titration regimen.
- Trial name
- ACTUAL (NCT00708344)
- Testing
- Irbesartan - Hydrochlorothiazide
- Where
- 16 sites in Algeria, Argentina and 14 more
- Volunteers
- 832 people
- Sponsor
- Sanofi
Atrial Fibrillation
Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
The objective of this study is to compare the efficacy and safety of dronedarone to that of amiodarone for the treatment of patients with atrial fibrillation.
- Trial name
- DIONYSOS (NCT00489736)
- Testing
- dronedarone (SR33589), amiodarone
- Where
- 23 sites in United States, Argentina and 21 more
- Volunteers
- 504 people
- Sponsor
- Sanofi
Atrial Fibrillation, Atrial Flutter
A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation
To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter (AF/AFL).
- Trial name
- ATHENA (NCT00174785)
- Testing
- dronedarone (SR33589)
- Where
- 37 sites in United States, Argentina and 35 more
- Volunteers
- 4,628 people
- Sponsor
- Sanofi
Head and Neck Neoplasms
NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)
Primary Objective: To estimate the overall response rate after neo-adjuvant chemotherapy of Docetaxel 75 mg/m2 in combination with Cisplatin 75 mg/m2 given for 3 cycles, and followed by conventional radiotherapy in UCNT.
- Trial name
- NCT00916097
- Testing
- DOCETAXEL(XRP6976)
- Where
- 3 sites in Algeria, Morocco and 1 more
- Volunteers
- 66 people
- Sponsor
- Sanofi
Major Depressive Disorder
Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder
The primary objective of the study is to compare, after 8 weeks, the efficacy of SR58611A vs. placebo in patients with Major Depressive Disorder who are on concomitant treatment with escitalopram.
- Trial name
- ALBERIO (NCT00432614)
- Testing
- SR58611A, escitalopram
- Where
- 13 sites in Belgium, Estonia and 11 more
- Volunteers
- 510 people
- Sponsor
- Sanofi
Major Depressive Disorders
Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder
Primary objective: To evaluate the long-term safety and tolerability of SR58611A (amibegron) patients with major depressive disorder (MDD).
- Trial name
- NCT00855530
- Testing
- amibegron (SR58611A)
- Where
- 11 sites in Argentina, Chile and 9 more
- Volunteers
- 527 people
- Sponsor
- Sanofi
Parkinson Disease
Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease
The primary objective is to assess the effect of SR57667B at the dose of 4 mg/d on the progression of Parkinson symptoms in patients with early PD.
- Trial name
- NCT00228150
- Testing
- SR57667B
- Where
- 13 sites in Austria, Canada and 11 more
- Volunteers
- 564 people
- Sponsor
- Sanofi